A Phase 1a/1b, Blinded, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti-Viral Activity, and Pharmacokinetics of ARB-1740 in Non Cirrhotic, HBV-DNA Negative and Positive Subjects with Chronic HBV Infection.
Phase of Trial: Phase I
Latest Information Update: 18 Aug 2017
Price : $35 *
At a glance
- Drugs ARB 1740 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Arbutus Biopharma
- 17 Aug 2017 Planned End Date changed from 6 Mar 2018 to 6 Nov 2017.
- 17 Aug 2017 Status changed from recruiting to discontinued.
- 22 Apr 2017 According to an Arbutus Biopharma media release, results from this trial are expected in 2H 2017.